Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis

PURPOSE: Mucosal melanoma is an aggressive malignancy with a poor response to conventional therapies. The efficacy and safety of nivolumab (a programmed death-1 checkpoint inhibitor), alone or combined with ipilimumab (a cytotoxic T-lymphocyte antigen-4 checkpoint inhibitor), have not been reported...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: D’Angelo, Sandra P., Larkin, James, Sosman, Jeffrey A., Lebbé, Celeste, Brady, Benjamin, Neyns, Bart, Schmidt, Henrik, Hassel, Jessica C., Hodi, F. Stephen, Lorigan, Paul, Savage, Kerry J., Miller, Wilson H., Mohr, Peter, Marquez-Rodas, Ivan, Charles, Julie, Kaatz, Martin, Sznol, Mario, Weber, Jeffrey S., Shoushtari, Alexander N., Ruisi, Mary, Jiang, Joel, Wolchok, Jedd D.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2017
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5559888/
https://ncbi.nlm.nih.gov/pubmed/28056206
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.67.9258
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados